NCT02409524View on ClinicalTrials.gov

An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

March 31, 2019

Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
BIOLOGICAL

AlloVax

Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)

BIOLOGICAL

AlloStim

AlloStim (ID) injection AlloStim (IV) infusion

BIOLOGICAL

CRCL

Autologous tumor-derived chaperone protein mixture

Trial Locations (1)

10400

National Cancer Institute of Thailand Address: 268/1 Rama Rd. Ratchathewi, Bangkok

Sponsors
All Listed Sponsors
lead

Mirror Biologics, Inc.

INDUSTRY

NCT02409524 - An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects | Biotech Hunter | Biotech Hunter